Medical technology software company ContextVision AB (OSE:CONTX) revealed on Monday that it has entered into a strategic partnership with the University of Washington School of Medicine to develop imaging-based biomarkers for metabolic dysfunction-associated steatotic liver disease (MASLD).

The collaboration aims to acquire a medical imaging dataset to improve screening and staging of the disease.

ContextVision, a leader in medical imaging solutions, is expanding into AI-driven data quality ultrasound. This initiative focuses on developing organ-specific imaging tools for physiological quantification. The partnership with the University of Washington's Department of Radiology and Division of Gastroenterology represents a key step in this strategy.

UW Medicine's extensive patient base with MASLD will contribute to a robust dataset for research. The goal is to enhance early detection and monitoring of the disease using ultrasound, potentially improving patient outcomes.